Skip to main content
Erschienen in: Supportive Care in Cancer 9/2011

01.09.2011 | Original Article

The post-treatment experience of cancer survivors with pre-existing cardiopulmonary disease

verfasst von: Heather Becker, Ruth Rechis, Sook Jung Kang, Adama Brown

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to explore the cancer experience of survivors with pre-existing diagnoses of heart and/or lung disease following active treatment.

Method

The Lance Armstrong Foundation recruited cancer survivors throughout the United States to complete a web-based survey to provide insight into post-treatment supportive care needs. Experts in survey methodology and oncology, as well as cancer survivors, provided input into the survey.

Results

Among the 2,307 respondents, 137 individuals had been told by their physicians that they had heart or lung problems. They were 50 years old on average, and most were more than 5 years past active treatment. Two thirds of these respondents reported pain for long periods, and 20% of them agreed that they now need help with everyday tasks that they did not need help with before their cancer. Among those who were tired, had no energy, or had trouble sleeping and/or resting, less than half (47%) agreed that they had received help with this problem. One third of these respondents indicated that they had decreased their physical activity since their cancer diagnosis because of fatigue, and 26% decreased their activities because of pain. More respondents indicated that their needs were met during their cancer treatment than afterwards.

Conclusions

Researchers and healthcare providers are urged to consider the unmet supportive care needs of cancer survivors with co-morbid conditions following active treatment, particularly the necessity for careful monitoring of their complex health conditions.
Literatur
1.
Zurück zum Zitat Ambrogi V, Pompeo E, Elia S, Pisolese GR, Mineo TC (2003) The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardio-Thorac 23:811–817CrossRef Ambrogi V, Pompeo E, Elia S, Pisolese GR, Mineo TC (2003) The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardio-Thorac 23:811–817CrossRef
2.
Zurück zum Zitat Aziz N (2002) Long term survivorship: late effects. In: Berger A, Portenov R, Weissman D (eds) Principles and practice of palliative care and supportive oncology, 2nd edn. Lippincott, Williams, and Wilkins, Philadelphia, PA, pp 1019–1033 Aziz N (2002) Long term survivorship: late effects. In: Berger A, Portenov R, Weissman D (eds) Principles and practice of palliative care and supportive oncology, 2nd edn. Lippincott, Williams, and Wilkins, Philadelphia, PA, pp 1019–1033
3.
Zurück zum Zitat Bellizzi KM, Rowland JH, Jeffery DD, McNeel T (2005) Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 23:8884–8593PubMedCrossRef Bellizzi KM, Rowland JH, Jeffery DD, McNeel T (2005) Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 23:8884–8593PubMedCrossRef
4.
Zurück zum Zitat Bennett JA, Brown P, Cameron L et al (2009) Changes in employment and household income during the 24 months following a cancer diagnosis. Support Care Cancer 17:1057–1064CrossRef Bennett JA, Brown P, Cameron L et al (2009) Changes in employment and household income during the 24 months following a cancer diagnosis. Support Care Cancer 17:1057–1064CrossRef
5.
Zurück zum Zitat Birim O, Kappetein PA, Bogers AJJC (2005) Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardio-Thorac 28:759–762CrossRef Birim O, Kappetein PA, Bogers AJJC (2005) Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardio-Thorac 28:759–762CrossRef
6.
Zurück zum Zitat Courneya KS, Friedenreich CM (1997) Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med 3:215–226PubMedCrossRef Courneya KS, Friedenreich CM (1997) Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med 3:215–226PubMedCrossRef
7.
Zurück zum Zitat Del Giudice ME, Grunfeld E, Harvey BJ et al (2009) Primary care physician's views of routine follow-up care of cancer survivors. J Clin Oncol 27:3338–3345PubMedCrossRef Del Giudice ME, Grunfeld E, Harvey BJ et al (2009) Primary care physician's views of routine follow-up care of cancer survivors. J Clin Oncol 27:3338–3345PubMedCrossRef
8.
Zurück zum Zitat De Marco MF, Janssen-Heijnen MLG, van der Heijden LH, Coebergh JWW (2000) Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 36:95–99PubMedCrossRef De Marco MF, Janssen-Heijnen MLG, van der Heijden LH, Coebergh JWW (2000) Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 36:95–99PubMedCrossRef
9.
Zurück zum Zitat De Rijke JM, Schouten LJ, ten Velde GPM, Wanders SL, Bollen ECM, Lalisan RI, van Dijck JAAM, Kramer GWP, van den Brandt PA (2004) Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46:233–245PubMedCrossRef De Rijke JM, Schouten LJ, ten Velde GPM, Wanders SL, Bollen ECM, Lalisan RI, van Dijck JAAM, Kramer GWP, van den Brandt PA (2004) Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46:233–245PubMedCrossRef
10.
Zurück zum Zitat Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200PubMedCrossRef Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200PubMedCrossRef
11.
Zurück zum Zitat Galvao DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 4:899–909CrossRef Galvao DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 4:899–909CrossRef
12.
Zurück zum Zitat Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG (2001) Comorbid illness and the early detection of cancer. South Med J 94:0038–4348 Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG (2001) Comorbid illness and the early detection of cancer. South Med J 94:0038–4348
13.
Zurück zum Zitat Hawfield A, Lovato J, Covington D, Kimmick G (2006) Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol 59:250–255PubMedCrossRef Hawfield A, Lovato J, Covington D, Kimmick G (2006) Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol 59:250–255PubMedCrossRef
14.
Zurück zum Zitat Janssen-Heijnen MLG, Maas HAAM, Houterman S, Lemmens VEPP, Rutten HJT, Coebergh SWW (2007) Comorbidity in older surgical cancer patients. Eur J Cancer 43:2179–2193PubMedCrossRef Janssen-Heijnen MLG, Maas HAAM, Houterman S, Lemmens VEPP, Rutten HJT, Coebergh SWW (2007) Comorbidity in older surgical cancer patients. Eur J Cancer 43:2179–2193PubMedCrossRef
15.
Zurück zum Zitat Johansson BBK, Holmberg L, Berglund IG, Sjoden PO, Glimelius BLG (2004) Determinants of cancer patients' utilization of hospital care within two years after diagnosis. Acta Oncol 43:536–544PubMedCrossRef Johansson BBK, Holmberg L, Berglund IG, Sjoden PO, Glimelius BLG (2004) Determinants of cancer patients' utilization of hospital care within two years after diagnosis. Acta Oncol 43:536–544PubMedCrossRef
16.
Zurück zum Zitat Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC (2009) Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 208:202–209PubMedCrossRef Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC (2009) Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 208:202–209PubMedCrossRef
17.
Zurück zum Zitat Louwman WJ, Janssen-Heijnen MLG, Houterman S, Voogd AC, van der Sangen MJC, Nieuwenhuijzen GAP, Coebergh JWW (2002) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785CrossRef Louwman WJ, Janssen-Heijnen MLG, Houterman S, Voogd AC, van der Sangen MJC, Nieuwenhuijzen GAP, Coebergh JWW (2002) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785CrossRef
18.
Zurück zum Zitat Mayer DK, Terrin NC, Menon U et al (2007) Health behaviors in cancer survivors. Oncol Nurs Forum 34:643–651PubMedCrossRef Mayer DK, Terrin NC, Menon U et al (2007) Health behaviors in cancer survivors. Oncol Nurs Forum 34:643–651PubMedCrossRef
19.
Zurück zum Zitat McCarthy EP, Ngo LH, Chirikos TN, Roetzheim RC, Li D, Drews RE, Iezzoni L (2007) Cancer stage at diagnosis and survival among persons with social security disability insurance on Medicare. Health Serv Res 42:611–628PubMedCrossRef McCarthy EP, Ngo LH, Chirikos TN, Roetzheim RC, Li D, Drews RE, Iezzoni L (2007) Cancer stage at diagnosis and survival among persons with social security disability insurance on Medicare. Health Serv Res 42:611–628PubMedCrossRef
20.
Zurück zum Zitat McDowell ME, Occhipinti S, Ferguson M et al (2010) Predictors of change in unmet supportive care needs in cancer. Psychooncol 19:508–516CrossRef McDowell ME, Occhipinti S, Ferguson M et al (2010) Predictors of change in unmet supportive care needs in cancer. Psychooncol 19:508–516CrossRef
21.
Zurück zum Zitat National Cancer Institute (2004) Living beyond cancer: finding a new balance. President's Cancer Panel, U.S. Government Printing Office, Washington, DC National Cancer Institute (2004) Living beyond cancer: finding a new balance. President's Cancer Panel, U.S. Government Printing Office, Washington, DC
22.
Zurück zum Zitat Paszat L, Pritchard K, Shi J (2003) Invasive breast cancer diagnosed among women 66–85 years of age: treatment variations by age, residence, and comorbidity. Radiother Oncol 69:S3 Paszat L, Pritchard K, Shi J (2003) Invasive breast cancer diagnosed among women 66–85 years of age: treatment variations by age, residence, and comorbidity. Radiother Oncol 69:S3
23.
Zurück zum Zitat Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. J Am Med Assoc 291:2441–2447CrossRef Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. J Am Med Assoc 291:2441–2447CrossRef
24.
Zurück zum Zitat Pollack L, Greer G, Rowland J et al (2005) Cancer survivorship: a new challenge in comprehensive cancer control. Cancer Causes Control 16(suppl 1):51–59PubMedCrossRef Pollack L, Greer G, Rowland J et al (2005) Cancer survivorship: a new challenge in comprehensive cancer control. Cancer Causes Control 16(suppl 1):51–59PubMedCrossRef
25.
Zurück zum Zitat Reigle BS (2006) The prevention of disablement: a framework for the breast cancer trajectory. Rehabil Nurs 31:174–179PubMed Reigle BS (2006) The prevention of disablement: a framework for the breast cancer trajectory. Rehabil Nurs 31:174–179PubMed
27.
Zurück zum Zitat Shack LG, Rachet B, Williams EMI et al (2010) Does the timing of comorbidity affect colorectal cancer survival? A population based study. Postgrad Med J 86:73–78PubMedCrossRef Shack LG, Rachet B, Williams EMI et al (2010) Does the timing of comorbidity affect colorectal cancer survival? A population based study. Postgrad Med J 86:73–78PubMedCrossRef
28.
Zurück zum Zitat Truong P, Canavan J, MacNeil M et al (2003) The effect of age and comorbidity on treatment selection and outcome in women with endometrial cancer. Radiother Oncol 69:S11 Truong P, Canavan J, MacNeil M et al (2003) The effect of age and comorbidity on treatment selection and outcome in women with endometrial cancer. Radiother Oncol 69:S11
29.
Zurück zum Zitat Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML (2004) Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 96:1322–1330PubMedCrossRef Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML (2004) Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 96:1322–1330PubMedCrossRef
Metadaten
Titel
The post-treatment experience of cancer survivors with pre-existing cardiopulmonary disease
verfasst von
Heather Becker
Ruth Rechis
Sook Jung Kang
Adama Brown
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0957-z

Weitere Artikel der Ausgabe 9/2011

Supportive Care in Cancer 9/2011 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.